Faster access than browser!
14 relations: Amiodarone, Asunaprevir, ATC code J05, Beacon Pharmaceuticals, Beclabuvir, Bristol-Myers Squibb, Buyers club, Discovery and development of NS5A inhibitors, Hepatitis C, NS5A, Simeprevir, Sofosbuvir, Sofosbuvir/daclatasvir, WHO Model List of Essential Medicines.
Amiodarone
Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of irregular heartbeats.
New!!: Daclatasvir and Amiodarone · See more »
Asunaprevir
Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.
New!!: Daclatasvir and Asunaprevir · See more »
ATC code J05
J05.
New!!: Daclatasvir and ATC code J05 · See more »
Beacon Pharmaceuticals
Beacon Pharmaceuticals Limited is a Bangladeshi pharmaceutical company that develops generic version of drug and commercializes therapeutics.
New!!: Daclatasvir and Beacon Pharmaceuticals · See more »
Beclabuvir
Beclabuvir (also known by the research name BMS-791325; abbreviated BCV) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection that has been studied in clinical trials.
New!!: Daclatasvir and Beclabuvir · See more »
Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City.
New!!: Daclatasvir and Bristol-Myers Squibb · See more »
Buyers club
A buyers club or buying club is a club organized to pool members' collective buying power, enabling them to make purchases at lower prices than are generally available, or to purchase goods that might be difficult to obtain independently.
New!!: Daclatasvir and Buyers club · See more »
Discovery and development of NS5A inhibitors
Nonstructural protein 5A (NS5A) inhibitors belong to a class of antiviral drugs called protease inhibitors.
New!!: Daclatasvir and Discovery and development of NS5A inhibitors · See more »
Hepatitis C
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver.
New!!: Daclatasvir and Hepatitis C · See more »
NS5A
Nonstructural protein 5A (NS5A) is a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication.
New!!: Daclatasvir and NS5A · See more »
Simeprevir
Simeprevir, sold under the trade names Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. Cure rates are in 80s to 90s percent. It may be used in those who also have HIV/AIDS. It is taken by mouth once daily for typically 12 weeks. Common side effects include feeling tired, headache, rash, itchiness, and sensitivity to sunlight. In those with previous hepatitis B infection, active disease may recur. It is not recommended in those with significant liver problems. During pregnancy when used with ribavirin it may cause harm to the baby while when used with sofosbuvir its safety is unclear. Simeprevir is a HCV protease inhibitor. Simeprevir was developed by Medivir AB and Janssen Pharmaceutica. It was approved for medical use in the United States in 2013. Simeprevir is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not available as a generic medication as of 2015. In the United Kingdom a course of treatment with ribavirin and peginterferon-alfa cost about £29,700 in 2015. In the United States a course of treatment with sofosbuvir was more than 171,000 in 2015 with the simeprevir component costing 66,360.
New!!: Daclatasvir and Simeprevir · See more »
Sofosbuvir
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir.
New!!: Daclatasvir and Sofosbuvir · See more »
Sofosbuvir/daclatasvir
Daclatasvir/sofosbuvir is a two-drug combination for the treatment of hepatitis C. It is given as a single daily pill containing daclatasvir, the viral NS5A inhibitor and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.
New!!: Daclatasvir and Sofosbuvir/daclatasvir · See more »
WHO Model List of Essential Medicines
The WHO Model List of Essential Medicines (EML), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system.
New!!: Daclatasvir and WHO Model List of Essential Medicines · See more »
Redirects here:
BMS-790052, C40H50N8O6, Daklinza.
